^
    Back
    Association details:
    Biomarker:KIT mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:Ayvakit (avapritinib) (CSF-1R inhibitor, PDGFR antagonist, mutant c-KIT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Drug-drug Interaction Study of Avapritinib and Midazolam

    Excerpt:
    ...Patient's tumor must have known KIT mutation 4....
    Trial ID:
    NCT04908176
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

    Excerpt:
    ...- Cohort 3: Participants must have a confirmed diagnosis of unresectable GIST without mutations in the PDGFRα gene exon 18, KIT gene exon 13, and KIT gene exon 14....
    Trial ID:
    NCT05381753
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncologist
    Title:

    Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least 3 Prior Lines of Therapy

    Published date:
    01/16/2021
    Excerpt:
    ORR in response-evaluable patients with GIST harboring KIT or non-D842V PDGFRA mutations and with ≥3 prior therapies (n = 103) was 17% (95% CI 10-25)....Avapritinib has manageable toxicity with meaningful clinical activity as fourth-line or later treatment in some patients with GIST with KIT or PDGFRA mutations.
    DOI:
    10.1002/onco.13674